|
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. |
80.00% |
|
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer |
80.00% |
|
A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group. |
80.00% |
|
Anthroposophic health care--different and home-like. |
80.00% |
|
Resveratrol |
80.00% |
|
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... |
80.00% |
|
Death by Lockdown |
80.00% |
|
DR. MIKAEL NORDFORS INTERVIEWED BY SONIA POULTON 04.02.2022 |
80.00% |
|
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. |
80.00% |
|
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds |
80.00% |
|
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.. |
80.00% |
|
The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. |
80.00% |
|
Antitumor properties and modulation of antioxidant enzymes' activity by Aloe vera leaf active principles isolated via supercriti |
80.00% |
|
Effect of some isoquinoline alkaloids on enzymatic activity of acetylcholinesterase and monoamine oxidase |
80.00% |
|
Induction of apoptosis in cultured Chinese hamster ovary cells by Ukrain and its synergistic action with etoposide. |
80.00% |
|
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking and |
80.00% |
|
Evaluation of anticancer activities of benzo phenanthridine alkaloid sanguinarine in oral squamous cell carcinoma cell line. |
80.00% |
|
Ukrain Debate 1: What is the active Substance of Ukrain? |
80.00% |
|
Possible association between nanobacteria and malignant microcalcifications in breast cancer. |
80.00% |
|
Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. |
80.00% |
|
Interaction between Ukrain and Naltrexone in the writhing syndrome test in mice |
80.00% |
|
Clinical applications of magnetic nanoparticles for hyperthermia. |
80.00% |
|
The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain |
80.00% |
|
66 year man. Cholangiocarcinoma |
80.00% |
|
National Cancer Institute, National Institute of Health: Developmental Therapeutics Program. NSC 631570: results of the Human Ce |
80.00% |
|
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. |
80.00% |
|
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. |
80.00% |
|
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. |
80.00% |
|
Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. |
80.00% |
|
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. |
80.00% |
|
Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy |
80.00% |
|
Regional hyperthermia in high-risk soft tissue sarcomas. |
80.00% |
|
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to... |
80.00% |
|
Be prudent of ketamine in treating resistant depression in patients with cancer. |
80.00% |
|
Newcastle disease virus as an oncolytic agent. |
80.00% |
|
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. |
80.00% |
|
High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. |
80.00% |
|
The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. |
80.00% |
|
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt |
80.00% |
|
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. |
80.00% |
|
Clinical studies of Ukrain in terminal cancer patients (phase II) |
80.00% |
|
Clinical experience of integrative cancer immunotherapy with GcMAF. |
80.00% |
|
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. |
80.00% |
|
Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled |
80.00% |
|
Complementary and alternative medicines taken by cancer patients |
80.00% |
|
Boswellic acids: biological actions and molecular targets. |
80.00% |
|
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate ca |
80.00% |
|
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. |
80.00% |
|
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. |
80.00% |
|
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocy.. |
80.00% |
|
Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour ce |
80.00% |
|
The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 ... |
80.00% |
|
Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma |
80.00% |
|
Ukrain therapy of recurrent breast cancer with lung metastases (case report) |
80.00% |
|
Melatonin as biological response modifier in cancer patients. |
80.00% |
|
Ukrain acts by inhibition of tubulin polymerization in normal and malignant cell lines. |
80.00% |
|
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse |
80.00% |
|
Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) |
80.00% |
|
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m |
80.00% |
|
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecula |
80.00% |
|
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma |
80.00% |
|
Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice. |
80.00% |
|
To widen the setting of cancer patients who could benefit from metronomic capecitabine. |
80.00% |
|
Bevacizumab for recurrent ependymoma. |
80.00% |
|
An Internet misadventure: bloodroot salve toxicity |
80.00% |
|
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient |
80.00% |
|
Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. |
80.00% |
|
Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients. |
80.00% |
|
The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. |
80.00% |
|
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expressio |
80.00% |
|
82 year old woman. Breast cancer with lymph and bone metastasis. |
80.00% |
|
Ukrain monotherapy in malignant melanoma (case report) |
80.00% |
|
A lipoxygenase inhibitor in breast cancer brain metastases. |
80.00% |
|
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. |
80.00% |
|
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer |
80.00% |
|
Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. |
80.00% |
|
Hypericine |
83.33% |
|
Mistletoe Therapy in Cancer |
83.33% |
|
82 year old man with prostate cancer |
85.00% |
|
Curcumin |
85.00% |
|
Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. |
85.00% |
|
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial |
85.00% |
|
The anti-angiogenic basis of metronomic chemotherapy. |
85.00% |
|
Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. |
85.00% |
|
Todoxin, the immune stimulant from Serbia |
86.36% |
|
Systems biology: a therapeutic target for tumor therapy. |
86.67% |
|
GcMAF-The cancer revolution from Japan |
87.50% |
|
Low dose "Metronomic" Chemotherapy |
89.00% |
|
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. |
90.00% |
|
Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention |
90.00% |
|
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... |
90.00% |
|
Immunomodulatory effects of opioids. |
90.00% |
|
RECURRENCE OF BRAIN TUMORS MAY BE PREVENTED WITH RUTA AND CALCAREA PHOSPHORICA |
90.00% |
|
Current perspectives on the medicinal potentials of Vernonia amygdalina Del. |
90.00% |
|
61 year old woman, Breast cancer with lymph, and lung metastasis |
90.00% |
|
A homeopathic approach to treat patients with advanced gallbladder, periampullary, and liver carcinomas: a report of 3 cases. |
90.00% |
|
Mycoplasma infections and different human carcinomas. |
90.00% |
|
Electromagnetic energy as a bridge between atomic and cellular levels in the genetics approach to cancer treatment. |
90.00% |
|
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. |
90.00% |
|
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prosta |
90.00% |
